Mar. 27 at 2:35 PM
$ABVX sitting around an ~
$8.5B market cap — and the narrative hasn’t changed, only the price has.
Whispers of ~
$200/share buyout interest (≈90% upside from here) keep the asymmetric setup very much alive. That kind of gap doesn’t sit idle forever if the thesis holds.
Key watch: maintenance data. If it stays strong and confirms the story, big pharma interest (think BP) could step in aggressively. That’s the catalyst everyone is waiting for.
I said don’t chase in the
$130–150 range… but this pullback? That’s where the risk/reward starts to flip in your favor.
Not financial advice, but this is exactly how early positioning gets built before the crowd catches on.
